GlucoFit
Improve the health and life of people with diabetes through an individualized therapy by providing an easy-to-use, integrated, data-driven solution for them and their doctors and diabetes coaches.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
N/A | Support Program | ||
| Total Funding | 000k | ||
Related Content
GlucoFit GmbH, established in Berlin in 2021, is a digital health company operating in the life sciences and healthcare sector. The firm was co-founded by Inka Benthin, who serves as CEO, and Dr. Matthias Ohliger, the CTO. Both founders are physicists who knew each other from their university research years. Benthin has a background in managing large-scale IT programs, while Ohliger has experience in developing digital transformation strategies for major corporations. A key driver for the company is Benthin's personal experience as a type-1 diabetic, which provides direct user insight within the leadership team.
The company's core offering is a mobile application and decision support system designed for individuals with diabetes, particularly type 1. The platform functions as a companion app that analyzes data from continuous glucose monitoring devices to provide personalized therapy recommendations. By applying artificial intelligence, the app identifies patterns and helps users understand the causes of high and low blood sugar levels, offering daily feedback and actionable insights to improve their diabetes management. Key features include a personal digital coach named "Lukie," a nutritional calculator, and motivational reminders. The app is designed to consolidate all relevant diabetes data in one place, which can then be shared with doctors to facilitate more precise treatment. GlucoFit operates on a B2B2C software-as-a-service (SaaS) model.
Since its founding, GlucoFit has secured seed funding from investors including IFB Innovationsstarter and Huge Thing. The product is developed with a scientific basis and is approved as a medical product, ensuring reliability and safety for its users. The company aims to digitize diabetes therapy by creating a solution that interconnects patients and their physicians through its data-driven platform.
Keywords: digital health, diabetes management, medical device, mobile application, personalized therapy, continuous glucose monitoring, artificial intelligence, SaaS, B2B2C, healthtech, type 1 diabetes, blood sugar management, Inka Benthin, Dr. Matthias Ohliger, Berlin startup, decision support system, patient data analytics, IFB Innovationsstarter, telemedicine, chronic disease management